- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00802828
Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions
March 15, 2012 updated by: Perrigo Company
Randomized, 2-Way Crossover, Bioequivalence Study of Famotidine 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fasting Conditions
Compare the rate and extent of absorption of famotidine 40 mg tablets, administered as 1 x 40 mg tablet under fasting conditions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- healthy men or women 18 years of age or older
- body mass index below 30.0 kg/m2
- willing to participate and sin a copy of the informed consent form
Exclusion Criteria:
- recent history of drug or alcohol addiction or abuse
- pregnant or lactating women
- history of allergic response to heparin, famotidine, other H2-receptor antagonists, or other related drugs
- evidence of a clinically significant disorder or whose laboratory results were deemed to be clinically significant
- recipient of any drugs as part of a research study within 30 days prior to study dosing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Test Product
|
|
Active Comparator: Reference Product
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Bioequivalence was assessed based on the pharmacokinetic variables, Cmax, AUCO-t and AUCO-infinity
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2004
Primary Completion (Actual)
June 1, 2004
Study Registration Dates
First Submitted
December 3, 2008
First Submitted That Met QC Criteria
December 4, 2008
First Posted (Estimate)
December 5, 2008
Study Record Updates
Last Update Posted (Estimate)
March 16, 2012
Last Update Submitted That Met QC Criteria
March 15, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 40103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioavailability
-
Initiator PharmaNot yet recruiting
-
Fundació EurecatURIACH, S.L.Completed
-
WockhardtCompletedBioavailabilityUnited States
-
Midwest Center for Metabolic and Cardiovascular...NaturmegaCompleted
-
University of AarhusCompletedBioavailabilityDenmark
-
Cessatech A/SSmerud Medical Research International AS; Dantrials ApsCompleted
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
Rousselot BVBABioTeSys GmbHCompleted
-
University of UtahCompleted
-
KGK Science Inc.ChromaDex, Inc.Completed
Clinical Trials on Famotidine Tablets, 40 mg
-
Perrigo CompanyCompleted
-
Eisai Inc.CompletedPurpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic PurpuraNetherlands
-
Valenta Pharm JSCCompletedInfluenza, Human | Common Cold | Acute Respiratory InfectionRussian Federation
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
Lexicon PharmaceuticalsCompletedDrug-drug InteractionUnited States
-
Mylan Pharmaceuticals IncCompletedHealthyUnited States
-
Mylan Pharmaceuticals IncCompletedHealthyUnited States
-
Teva Pharmaceuticals USACompleted
-
Tobira Therapeutics, Inc.Completed